MEDI 358 |
| Imatinib, a BCR-ABL tyrosine kinase inhibitor, is the standard of care for patients with chronic myelogenous leukemia (CML). Unfortunately refractory response due to Imatinib treatment arises because of point mutations within the ABL kinase domain of BCR-ABL. These mutations interfere with Imatinib binding. Specifically, the T315I mutation accounts for about 15 percent of cases in which CML patients develop resistance to Imatinib. The T315I mutation also shows resistance to Dasatinib, a newer drug that has demonstrated effectiveness in Imatinib resistant patients by targeting all the clinically relevant mutants except the T315I mutant. Using molecular modeling, we have identified elements in Imatinib and Dasatinib that prevent effective binding to the ABL-T315I mutant. We have developed and optimized a series of ABL-T315I inhibitors to mediate the deficiency found in Dasatinib. We will present design elements that provide potency against the T315I mutant along with our optimization strategy. |
|
Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster
Sci-Mix
Division of Medicinal Chemistry |